The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer’s Disease and Beyond by Bastian Dislich & Stefan F. Lichtenthaler
REVIEW ARTICLE
published: 17 February 2012
doi: 10.3389/fphys.2012.00008
The membrane-bound aspartyl protease BACE1: molecular
and functional properties in Alzheimer’s disease and
beyond
Bastian Dislich and Stefan F. Lichtenthaler*
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
Edited by:
Raquel Marin, Universidad de La
Laguna, Spain
Reviewed by:
Giuseppina Tesco, Tufts University,
USA
Mikko Hiltunen, University of Eastern
Finland, Finland
*Correspondence:
Stefan F. Lichtenthaler , German
Center for Neurodegenerative
Diseases (DZNE), site Munich,
Schillerstrasse 44, 80336 Munich,
Germany.
e-mail: stefan.lichtenthaler@
dzne.lmu.de
The β-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease involved
in Alzheimer’s disease (AD) pathogenesis and in myelination. BACE1 initiates the genera-
tion of the pathogenic amyloid β-peptide, which makes BACE1 a major drug target for AD.
BACE1 also cleaves and activates neuregulin 1, thereby contributing to postnatal myeli-
nation, in particular in the peripheral nervous system. Additional proteins are also cleaved
by BACE1, but less is known about the physiological consequences of their cleavage.
Recently, new phenotypes were described in BACE1-deﬁcient mice. Although it remains
unclear through which BACE1 substrates they are mediated, the phenotypes suggest a
versatile role of this protease for diverse physiological processes.This review summarizes
the enzymatic and cellular properties of BACE1 as well as its regulation by lipids, by tran-
scriptional, and by translational mechanisms.The main focus will be on the recent progress
in understanding BACE1 function and its implication for potential mechanism-based side
effects upon therapeutic inhibition.
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INTRODUCTION: APP PROCESSING AND ALZHEIMER’S
DISEASE
Alzheimer’s disease (AD) represents the leading cause of demen-
tia worldwide. It is the most common neurodegenerative disease
and is characterized by two deﬁning pathological hallmarks, extra-
cellular amyloid plaques and intracellular neuroﬁbrillary tangles
(Ballard et al., 2011). The amyloid hypothesis states that the
main constituent of amyloid plaques, the 39–43 amino acid long
amyloid-β-peptide (Aβ), is responsible for the initiation of a
neurotoxic cascade that ultimately leads to neuronal death and
dementia (Hardy and Selkoe, 2002; Haass and Selkoe, 2007). Aβ
itself is liberated from the large type I transmembrane amyloidpre-
cursor protein (APP) in a stepwise process referred to as regulated
intramembrane proteolysis (RIP). RIP in general controls intra-
and intercellular communication through the release of extracel-
lular and cytosolic proteolytic fragments thatmay serve as versatile
signaling molecules or are further degraded (Brown et al., 2000;
Lichtenthaler et al., 2011). Ectodomain shedding, the ﬁrst step of
RIP, results in the release of the soluble APP ectodomain (APPs)
into the extracellular space and is carried out by either one of two
alternative protease activities. The molecular identity of these pro-
tease activities was unknown for many years, which led to the still
established terminology of α- and β-secretase.
In the amyloidogenic, β-secretase dependent pathway, shed-
ding occurs within the ectodomain of APP in close proximity to
the membrane and is mediated by the membrane-bound aspartyl
protease β-site APP cleaving enzyme 1 (BACE1, β-secretase,
memapsin-2, ASP-2; Hussain et al., 1999; Sinha et al., 1999; Vas-
sar et al., 1999; Yan et al., 1999; Lin et al., 2000; Figure 1). The
remaining membrane-bound APP C-terminal fragment (CTF)
bears the N-terminus of Aβ and is processed in a second step
within its transmembrane domain by the GxGD-type aspartyl
proteaseγ-secretase. Theγ-secretase complex consists of four inte-
gralmembrane proteins, including the catalytic subunit presenilin,
and is able to cleave its substrates within the hydrophobic envi-
ronment of the lipid bilayer (Steiner et al., 2008). This cleavage
generates the Aβ C-terminus and liberates the Aβ peptide into the
extracellular space, whereas the APP intracellular domain (ICD)
is released into the cytosol. Due to the heterogeneous nature of
γ-secretase cleavage, Aβ species of different length are produced,
including the pathogenic 42-amino acid long Aβ42, whose toxic
properties have been summarized in a recent review (O’Brien and
Wong, 2011). In the non-amyloidogenic pathway, a third prote-
olytic activity, referred to as α-secretase (Lichtenthaler et al., 2011),
precludes Aβ formation by cleaving APP within the Aβ domain,
and releasing the soluble APPsα fragment into the extracellular
space (Esch et al., 1990; Figure 1). ADAM10, a member of the
ADAM (a disintegrin and metalloprotease) family of proteases,
has α-secretase activity in vitro and in vivo and has been identiﬁed
as the constitutively cleaving α-secretase in neurons (Lammich
et al., 1999; Postina et al., 2004; Jorissen et al., 2010; Kuhn et al.,
2010). Other metalloproteases may also act as α-secretases, but
appear to cleave APP only after pharmacological activation or
overexpression (Buxbaum et al., 1998; Koike et al., 1999; Naus
et al., 2006). BACE1 is the rate-limiting and principal enzyme
responsible for Aβ generation in neurons. Deletion of BACE1 via
homologous recombination in mouse models of AD completely
abolishes Aβ generation in the brain (Cai et al., 2001; Luo et al.,
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FIGURE 1 | Proteolytic processing of the BACE1 substrates APP and
NRG1. (A) Regulated intramembrane proteolysis of APP occurs by two
alternative pathways. In the amyloidogenic pathway, ectodomain shedding
by BACE1 releases the soluble APP ectodomain and generates the
N-terminus of the Aβ peptide. The membrane-bound CTF (C99) is then
further processed by γ-secretase, which releases the Aβ peptide into the
extracellular space and the APP intracellular domain (AICD) into the cytosol
where it is rapidly degraded. In the alternative, anti-amyloidogenic pathway,
ectodomain shedding is mediated by ADAM10. Cleavage occurs in the
middle of the Aβ domain and yields the soluble APP ectodomain and a CTF
(C83), which is further processed by γ-secretase to generate the secreted
p3 peptide (not shown). (B) Ectodomain shedding of type III NRG1 by
BACE1 or ADAM10 occurs C-terminally of the EGF-like domain and
generates a large NTF as well as a shorter CTF. Cleavage by BACE1 leads to
a slightly larger NTF, that exerts signaling function. Cleavage within the
EGF-like domain by ADAM17 appears to render the resulting NTF inactive
(not shown). The remaining CTF is further processed by γ-secretase in
order to yield the NRG1-ICD.
2001; Roberds et al., 2001). Its therapeutic inhibition should there-
fore prevent the formation of all Aβ species and be beneﬁcial for
the treatment of AD. Besides BACE1, additional proteases with
minor, regulated β-secretase activity, such as the cysteine-protease
cathepsin B, may contribute to Aβ levels in the brain, suggest-
ing that their inhibition may be of additional therapeutic beneﬁt
(Haque et al., 2008; Hook et al., 2008, 2011). However, much less
is known about the pathophysiological relevance of cathepsin B
compared to BACE1.
Since its discovery in 1999 by ﬁve independent research groups
(Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan
et al., 1999; Lin et al., 2000), BACE1 is a major drug target for AD.
Extensive efforts toward an understanding of BACE1 physiology
and pathophysiology as well as the development of potent BACE1
inhibitors have been made. This review focuses on the latest ﬁnd-
ings and current developments in BACE1 research. We will ﬁrst
describe the role of BACE1 in AD as well as the basic cell biol-
ogy of this protease. Next we summarize the transcriptional and
translational regulation of BACE1 in health and disease. After dis-
cussing the role of lipid microdomains on BACE1 activity, we will
turn to BACE1 substrates with a focus on the functional conse-
quences of the generated proteolytic fragments. In order to safely
reduce Aβ levels in AD, a detailed understanding of BACE1 sub-
strate processing and its implications upon therapeutic inhibition
is necessary. Different approaches toward therapeutic inhibition
as well as future perspectives of BACE1 research will be addressed
in the last part of our review.
BACE1 CELL BIOLOGY
The 501 amino acid long type I transmembrane protein BACE1,
together with its homolog BACE2, belongs to the family of pepsin
and retroviral aspartic proteases. The single transmembrane
domain, a unique feature amongst aspartic proteases, exposes the
active site toward the luminal side and links the ectodomain to
the 21 amino acid long cytosolic tail (Figure 2). The active site
features the critical aspartic acid residues within two character-
istic D-T/S-G-T/S motifs. Like other aspartyl proteases, BACE1
requires both aspartates for its activity (Hussain et al., 1999; Vas-
sar et al., 1999; Bennett et al., 2000b). However, because BACE1
forms dimers, it appears possible that the two monomers pro-
vide one aspartate each. Evidence for this scenario comes from
a study showing that mutation of the aspartate within the C-
terminal DSGT motif does not affect BACE1 activity (Schmechel
et al., 2004). In the endoplasmic reticulum (ER), BACE1 is ini-
tially synthesized as a zymogen and subjected to N-glycosylation,
palmitoylation, transient acetylation, and disulﬁde bridge forma-
tion (Haniu et al., 2000; Benjannet et al., 2001; Costantini et al.,
2007; Ko and Puglielli, 2009; Vetrivel et al., 2009; Figure 2). Full
maturation occurs in the Golgi compartment, where complex gly-
cosylation and removal of the prodomain by furin prohormone
protein convertases lead to the 70 kDa form (Bennett et al., 2000b;
Capell et al., 2000; Benjannet et al., 2001). The zymogen form
already possesses signiﬁcant proteolytic activity,which is enhanced
about twofold after removal of the prodomain (Creemers et al.,
2001; Benjannet et al., 2004). Rather than suppressing enzymatic
activity, the prodomain facilitates correct folding of the protease
domain (Shi et al., 2001).
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FIGURE 2 | Structural organization of BACE1 (active isoform of 501
amino acids). Schematic diagram of the domain structure,
post-translational modiﬁcations and interaction motifs of BACE1.The active
sites motifs DTGS and DSGT at position 92–95 and 289–292 are marked as
stars, the critical aspartic residues are highlighted in red. The DISLL motif at
the cytosolic domain is recognized by GGA proteins and serves as an
endosomal targeting signal. Glycosylation sites are depicted as sugar
“trees,” palmitoylation sites as fatty acid chains. S–S, disulﬁde bond
(connecting amino acids 216–420, 278–443, 330–380); P, phosphorylation
site; Ub, ubiquitination site.
After transport to the plasma membrane, the dileucine motif
DISLL at position 496–500 in the cytoplasmic domain promotes
BACE1 trafﬁcking to early endosomal compartments (Huse et al.,
2000). A recent study suggests that this sorting event is controlled
by the small GTPase ARF6 in a clathrin-independent fashion,
in contrast to the clathrin-dependent endosomal sorting of APP
(Sannerud et al., 2011). Phosphorylation of the dileucine motif at
serine 498 and interaction with Golgi-localized γ-ear-containing
ARF-binding proteins (GGAs) is responsible for the retrieval from
early endosomes to late endosomes and the trans-Golgi-network
(TGN; He et al., 2002, 2003, 2005; von Arnim et al., 2004, 2006;
Wahle et al., 2005). In addition, retrograde BACE1 trafﬁcking
depends on the cytosolic domain of the Vps10p homolog Sor-
tilin, most likely via retromer complex or GGA dependent sorting
mechanisms (Finan et al., 2011). Recycling of BACE1 from the
TGNand endosomal compartments to the plasmamembrane con-
tributes to the relatively slow turnover rate of BACE1 (Walter et al.,
2001; He et al., 2005; Wahle et al., 2005). Finally, monoubiquitina-
tion at lysine 501 promotes lysosomal degradation, a process that
depends on the recognition of the ubiquitinated lysine residue by
GGA3 (Kang et al., 2010). Depletion of GGA3 enhances BACE1
activity andAβ generation in vitro and reduced GGA3 protein lev-
els correlate inversely with BACE1 protein levels in AD patients
(Tesco et al., 2007; Santosa et al., 2011). GGA3 depletion and sub-
sequent stabilization of BACE1 have been proposed to follow the
reduced expression of the neuroprotective protein seladin-1 under
stress conditions (Sarajarvi et al., 2009). Shedding by ADAMs,
which releases the BACE1 ectodomain into extracellular space, and
proteasomal degradation, could be responsible for a minor part of
BACE1 turnover (Benjannet et al., 2001; Hussain et al., 2003; Qing
et al., 2004). However, the inhibition of BACE1 shedding after
treatment with metalloprotease inhibitors does not inﬂuence Aβ
generation (Hussain et al., 2003).
ENZYMATIC PROPERTIES AND CELLULAR LOCALIZATION
β-Site APP cleaving enzyme 1 has an acidic pH-optimum (Vassar
et al., 1999; Gruninger-Leitch et al., 2002; Shimizu et al., 2008)
and cleaves its substrates mostly in the acidic early endosomal and
trans-Golgi compartments, where also Aβ generation takes place
(Haass et al., 1993; Koo and Squazzo, 1994; Vassar et al., 1999;
Capell et al., 2000; Gruninger-Leitch et al., 2002). After internal-
ization from the plasma membrane, wild-type APP is processed
in early endosomes. As indicated above, endocytosis and endo-
somal transport of APP and BACE1 occur via distinct pathways.
Interfering with either one, e.g., by knockdown of ARF6 or mod-
ulation of APP endocytosis via clathrin-dependent mechanisms,
alters the shedding of APP by BACE1 (Chyung and Selkoe, 2003;
Neumann et al., 2006; Schobel et al., 2006, 2008; Sannerud et al.,
2011). In contrast, the processing of Swedish APP (APPSWE), a
rare genetic double mutation leading to familial early-onset AD
(Mullan et al., 1992) occurs along the secretory pathway (Haass
et al., 1995). The responsible amino acid changes at position-1
and -2 of Aβ enhance the proteolytic activity of BACE1 and there-
fore Aβ production (Citron et al., 1992). Although the secreted
form of BACE1 processes peptide substrates in vitro, efﬁcient pro-
cessing of APP by BACE1 requires the membrane-bound form,
ensuring the proper spatial interaction between protease and sub-
strate at the membrane surface (Yan et al., 2001; Gruninger-Leitch
et al., 2002). In mouse and human brain, native BACE1 occurs as
a dimer. Dimerization via the ectodomain is dependent on mem-
brane attachment and increases BACE1 afﬁnity and turnover rate
toward APPSWE-like peptides when compared to the monomeric,
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soluble form (Schmechel et al., 2004; Westmeyer et al., 2004). The
different enzymatic properties of monomeric and dimeric BACE1
need to be considered in future drug screening and development
processes.
BACE1 STRUCTURE
The protease domain of BACE1 features the typical bilobal struc-
ture of aspartic proteases, showing a high degree of conservation
with pepsin and BACE2. The active site cleft is located between the
N- and C-terminal lobes and partially shielded by an antiparallel
hairpin loop known as “ﬂap,” which controls substrate access and
proteolytic speciﬁcity (Hong et al., 2000; Ostermann et al., 2006).
The main structural feature that sets BACE1 and BACE2 aside
from other aspartic proteases is the enlarged molecular bound-
ary of the catalytic domain. This is due to four helical or loop-like
insertions and a carboxyterminal extension in theC-terminal lobe,
possibly mediating associations with other cell surface molecules.
Overall the BACE1 active cleft is broader, less hydrophobic, and
more open when compared to other aspartic proteases, allowing
the accommodation of up to 11 substrate residues (Hong et al.,
2000; Turner et al., 2005). The unusually large active site poses
a major challenge in the development of potent small molecule
inhibitors in drug development.
EXPRESSION PATTERN OF BACE1
Consistent with its role as β-secretase, the highest expression lev-
els and enzymatic activity of BACE1 are found in brain (Sinha
et al., 1999; Vassar et al., 1999; Yan et al., 1999). This is mainly
due to neuronal expression, as expression levels in glial cells are
very low (Laird et al., 2005; Harada et al., 2006; Zhao et al., 2007).
In mouse brain, BACE1 expression peaks during early postnatal
stages, with highest expression levels found in the cortex, hip-
pocampus, and cerebellum (Irizarry et al., 2001; Willem et al.,
2006). Disruption of entorhinal cortex afferents to the hippocam-
pus and immunoﬂuorescence studies suggest that BACE1 localizes
to axonal membranes within neurons and is actively transported
to synaptic nerve terminals, resulting in the release of Aβ at the
synaptic cleft (Lazarov et al., 2002; Sheng et al., 2003). In contrast,
one study reports mainly somatodendritic localization of APP and
BACE1 within cultured polarized hippocampal neurons and ﬁnds
that the bulk of APPsβ and Aβ fragments is recovered from soma-
todendritic and not axonal compartments (Sannerud et al., 2011).
Besides brain tissue, high BACE1 mRNA levels are also found in
the pancreas. Due to alternative splicing and post-transcriptional
inactivation enzymatic activity is comparatively low (Sinha et al.,
1999; Bodendorf et al., 2001; Ehehalt et al., 2002; Molinari et al.,
2002; Mowrer and Wolfe, 2008). The pancreatic isoforms of
BACE1 may not cleave APP, but other substrates instead, such as
enteropeptidase,whichwas recently identiﬁed as a possible BACE1
substrate in pancreas (Bodendorf et al., 2001; Hoffmeister et al.,
2009). Low expression levels are found in the remainder of the
peripheral organs,which is in agreement with the observation that
Aβ is producedbymost cell lines, regardless of their tissueof origin.
TRANSCRIPTIONAL AND TRANSLATIONAL REGULATION OF
BACE1 ACTIVITY
A complex interplay of transcriptional, translational, and post-
translational mechanisms regulates BACE1 activity. At the
transcriptional level, numerous mechanisms regulating BACE1
activity have been described. Hypoxic and oxidative cell stress,
mediated by hypoxia-inducible factor 1α (HIF1α), the lipid perox-
idation product hydroxy-non-enal (HNE), the c-JUN N-terminal
kinase (JNK)/c-JUN pathway, and others, has been shown to
increase BACE1 mRNA levels (Yasojima et al., 2001; Holsinger
et al., 2002; Tamagno et al., 2005, 2008, 2009; Zhang et al., 2007).
Not all previous work on the transcriptional and translational reg-
ulation of BACE1 can be cited at this point and we refer the reader
to two excellent reviews for further information (Rossner et al.,
2006; Stockley and O’Neill, 2008). However, most of these studies
are based on in vitro observations. The physiological relevance for
AD pathogenesis remains unclear, as BACE1 transcript levels are
not signiﬁcantly altered in AD brains (Preece et al., 2003; Matsui
et al., 2007; Hebert et al., 2008). On the contrary, BACE1 protein
levels are increased two- to ﬁvefold in about 30% of patients with
sporadic AD, supporting the assumption of disease-relevant post-
transcriptional regulatory mechanisms (Fukumoto et al., 2002;
Holsinger et al., 2002; Preece et al., 2003; Yang et al., 2003; Li et al.,
2004; Hebert et al., 2008).
Indeed, three distinct mechanisms have been described con-
trolling the translation of BACE1. First, the large 5′ untranslated
region (5′ UTR) of the BACE1 transcript represses translation in a
constitutive fashion, as demonstrated in several cell culture studies
(De Pietri Tonelli et al., 2004; Lammich et al., 2004; Rogers et al.,
2004; Zhou and Song, 2006; Mihailovich et al., 2007). Mutagenesis
studies identiﬁed the GC-rich strand of the 5′ UTR as an effec-
tive translational barrier, preventing ribosomal binding (Lammich
et al., 2004). Further mechanisms such as ribosomal shunting by
binding of ribosomes to upstream ORFs and subsequent prema-
ture ribosomal dissociation have been proposed (Rogers et al.,
2004). It is currently unknown whether regulatory proteins bind
to and therefore modulate the extent of 5′ UTR mediated trans-
lational repression. However, a recent study demonstrated that
the translational block can be partly relieved under conditions
of energy deprivation in the brain, which suggests a direct link
between reduced brain metabolism and sporadic AD (Velliquette
et al., 2005). Post-transcriptionally elevated BACE1 and Aβ lev-
els were found upon acute pharmacologic reduction of energy
metabolism in mice overexpressing APPSWE. In vitro and in vivo,
phosphorylation of the translation initiation factor eIF2a results
in the increased translation of BACE1 mRNA, in a mechanism
that bypasses the repressive features of the 5′ UTR and that is typ-
ical of genes involved in the cellular stress response (Schroder and
Kaufman, 2006; O’Connor et al., 2008). A pathogenic increase in
BACE1 activity could therefore stem from a physiologic role in the
neuronal stress response.
A second mechanism of BACE1 translational regulation is
based on studies of miRNA expression proﬁles in patients with
sporadic AD, where a link between the downregulation of the
miRNA clustermiR-29a/b-1 andmiRNA-107 and a corresponding
increase in BACE1 protein levels was suggested. A direct relation-
ship is supported by the presence of binding sites for the identiﬁed
miRNAs within the BACE1 3′ UTR and cell culture reporter assays
(Hebert et al., 2008; Wang et al., 2008).
A third mechanism regulating BACE1 translation in vitro and
in vivo is a non-coding BACE1 antisense transcript (BACE1-AS).
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BACE1-AS is elevated inAD and surprisingly stabilizes the BACE1
mRNA, resulting in increased BACE1 protein levels and enhanced
Aβ42 production (Faghihi et al., 2008). Furthermore, Aβ42 stimu-
lates BACE1-AS expression, resulting in a feed-forward loop that
potentially drives disease progression.
THE ROLE OF THE LIPID ENVIRONMENT ON BACE1 ACTIVITY
In vivo, active BACE1 localizes to endosomal and trans-Golgi com-
partments.However, the precise localizationwithin themembrane
microenvironment and the related consequences toward BACE1
activity remain controversial. On the one hand, BACE1 and APP
in vivo and in vitro partially localize to lipid raft domains enriched
in cholesterol and sphingolipids, and enhanced targeting of BACE1
to these microdomains via addition of a GPI-anchor enhances Aβ
production (Riddell et al., 2001; Tun et al., 2002; Cordy et al., 2003;
Ehehalt et al., 2003; Kawarabayashi et al., 2004; Crameri et al.,
2006; Hattori et al., 2006). Feeding mice a high cholesterol diet,
which promotes lipid raft formation, increases Aβ levels, whereas
the disruption of lipid rafts upon depletion of cellular cholesterol
levels has the opposite effect (Simons et al., 1998; Fassbender et al.,
2001; Refolo et al., 2001; Cordy et al., 2003). On the other hand,
a study focusing on endogenous APP and BACE1 in hippocam-
pal neurons suggests that the main pool of APP resides outside
of lipid rafts, unable to be accessed by BACE1 (Abad-Rodriguez
et al., 2004).Moderate reductions in cholesterol levels increasedAβ
production, probably by disturbing raft architecture and therefore
enhancingBACE1 andAPP contact.However, strong reductions in
cholesterol decrease Aβ production presumably as result of direct
BACE1/γ-secretase inhibition (Kaether and Haass, 2004).
Lipid raft association of BACE1 is dependent on the S-
palmitoylation of four cysteine (Cys474/478/482/485) residues
at the boundary between the cytoplasmic and transmembrane
domain (Benjannet et al., 2001; Vetrivel et al., 2009). After muta-
tion of these residues, raft association is lost, without affecting
protein stability, subcellular localization, and proteolytic activity
toward APP in neuronal and non-neuronal cultured cells, sug-
gesting that BACE1 efﬁciently cleaves APP in raft and non-raft
environments. These results challenge the previous studies that
are based on cholesterol depletion (Simons et al., 1998; Fassben-
der et al., 2001; Refolo et al., 2001; Cordy et al., 2003), which has
pleiotropic effects on membrane morphology and vesicular traf-
ﬁcking (Rodal et al., 1999; Wang et al., 2000; Hao et al., 2004).
More in vivo studies focusing on endogenous APP and selectively
disturbing the lipid raft association of BACE1 are needed to resolve
these contradictory issues.
A direct effect on BACE1 activity by the active lipid metabolite
sphingosine-1-phosphate has been shown. Sphingosine is phos-
phorylated by sphingosine kinase 1 and 2 to generate sphingosine-
1-phosphate that ultimately binds to the C-terminal and trans-
membrane region of BACE1, activating its proteolytic activity
(Takasugi et al., 2011). Knockdown or inhibition of sphingo-
sine kinase 2 as well as overexpression of S1P degrading enzyme
reduced Aβ levels in cultured cells. In line with in vitro results,
stereotaxic injection of sphingosine kinase inhibitors reduced
brain Aβ loads in wild-type and APP transgenic mouse lines. Fur-
thermore, levels of sphingosine kinase 2 were found to be elevated
in AD brain.
BACE1 SUBSTRATES
Two years after the discovery of BACE1, the ﬁrst knockout mouse
lines were generated. These mice do not produce C99 or Aβ, fur-
ther validating BACE1 as the sole β-secretase in vivo. Initially,
overt developmental or adult phenotypes in BACE1−/− mice
were not detected, encouraging treatment of AD by therapeu-
tic inhibition of BACE1 without signiﬁcant adverse effects (Cai
et al., 2001; Luo et al., 2001; Roberds et al., 2001; Dominguez
et al., 2005). However, later studies uncovered multiple devel-
opmental and behavioral changes, suggesting that BACE1 has
diverse physiological roles. As the function of a protease is deﬁned
by its substrates, the identiﬁcation and characterization of novel
BACE1 substrates remains one of the key challenges in current
AD research, providing insights into BACE1 physiology, substrate
speciﬁcity, potential side effects upon therapeutic inhibition, and
biomarker development. So far, all known BACE1 substrates have
been identiﬁed by candidate approaches, some of them under
overexpressing conditions, where BACE1 may cleave substrates
that are not processed in vivo, for example proteins that reside in
the ER. Known BACE1 substrates (summarized in Table 1) will
be discussed below, in order of evidence regarding their in vivo
cleavage and the related functional consequences of the resulting
proteolytic fragments. APP, type III neuregulin 1, the β-subunits
2 and 4 of voltage-gated sodium channels (VGSCs), and the β-
galactoside α2, 6-sialyltransferase belong to the group of BACE1
substrates where the functional relevance of substrate cleavage has
been demonstrated in vivo.
Despite being a prominent substrate, the physiological func-
tion of APP and its shedding by BACE1 remains unclear. Genetic
deletion of full length APP in mice leads to a reduction in brain
and body weight, memory deﬁcits and reduced grip strength,
and can be rescued by APPsα (Ring et al., 2007). The addi-
tional knockout of the APP homolog amyloid precursor pro-
tein 2 (APLP2) results in perinatal lethality and neuromuscu-
lar synapse defects (Muller et al., 1994; von Koch et al., 1997).
APPsβ actively regulates transthyretin and Klotho expression lev-
els, but fails to rescue the lethality and neuromuscular synapse
defects present in APP/APLP2 knockout mice (Li et al., 2010).
Upon trophic withdrawal, APPsβ is processed by a yet uniden-
tiﬁed mechanism to yield a 35 kDa fragment (N-APP) that
binds to death receptor 6 and triggers a widespread proapop-
totic signal that may speed up neurodegeneration (Nikolaev et al.,
2009). Thus, APPsα and APPsβ apparently have different func-
tions. Future studies on the biology of APP and its homologs
could provide links to the complex phenotype of BACE1−/−
mice. Besides APP, APLP1 and 2 are also processed by BACE1
in vivo and in vitro (Yanagida et al., 2009; Sala Frigerio et al.,
2010; Hogl et al., 2011). The physiological function of APLP1
and APLP2 shedding by BACE1 is currently unknown. Wild-
type APP and its homologs are considered relatively poor sub-
strates, as BACE1 binds preferably to APPSWE-like peptides,
which feature bulky hydrophobic residues such as leucine and
phenylalanine at position P1 (reviewed in Stockley and O’Neill,
2008). However, this assumption is based on in vitro assays
using peptide substrates and neglects the proper spatial orien-
tation of the full length substrate and protease within the lipid
bilayer.
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BACE1 SUBSTRATES: TYPE III NEUREGULIN 1
The most consistent link between a BACE1 substrate and the
related phenotype of BACE1−/− mice has been established for
type III neuregulin 1 (NRG1). BACE1−/− mice show prominent
hypomyelination in the peripheral nervous system, phenocopying
mice haploinsufﬁcient in the EGF-like growth factor NRG1 (Hu
et al., 2006; Willem et al., 2006). NRG1 signaling via its cognate
ErbB2–ErbB4 receptors is essential for the initiation of myelination
and the regulationof myelin sheath thickness during development.
Full activationmay require theproteolytic liberationof the luminal
EGF-like domain (Falls, 2003; Sagane et al., 2005; Birchmeier and
Nave, 2008; Brinkmann et al., 2008), which is located in the loop
connecting the two transmembrane domains of type IIINRG1 and
complementing the hairpin shaped structure (Figure 1). An initial
shedding event occurs at the juxtamembrane region C-terminal of
the EGF-like domain and generates a shorter C-terminal stub and
a larger N-terminal fragment (NTF), which now exposes the EGF-
like domain for juxtacrine signaling (Mei and Xiong, 2008). A
second shedding event might then release the EGF-like domain
into the extracellular space, allowing for paracrine signaling, as
shown for type I NRG1(reviewed in Willem et al., 2009; Figure 1).
The initial shedding of type III NRG1 is mediated by BACE1 and
ADAM10, with the BACE1 cleavage sites eight amino acids down-
stream of the ADAM 10 cleavage site, therefore in inverse order
when compared to the proteolytic processing of APP. Interest-
ingly, upon knockdown and inhibitor treatment of ADAM10 and
BACE1, only the loss of the NRG1-NTF generated by BACE1 has
a signiﬁcant impact on myelination in a Schwann cell and neu-
ron co-culture system (Luo et al., 2011). Since full length NRG1
accumulates in BACE1−/− mice, the physiologic role of BACE1
in myelination is presumably mediated through NRG1 activation
via ectodomain shedding (Hu et al., 2006; Willem et al., 2006).
BACE1-driven myelination is counteracted byADAM17,which
partially cleaves in the middle of the EGF-like domain. Reduction
of ADAM17 activity in vivo is sufﬁcient to rescue the hypomyeli-
nation phenotype of type III NRG1 haploinsufﬁcient mice (La
Marca et al., 2011). Whether NRG1-dependent myelination in
the central nervous system is also altered in BACE1−/− mice
remains uncertain, as this was reported by one group but not
by others (Hu et al., 2006; Willem et al., 2006). One study sug-
gests that BACE1 in conjunction with type III NRG1 also reg-
ulates remyelination after sciatic nerve crush injury and there-
fore may be of importance for myelin maintenance in adults
(Hu et al., 2008). Unexpectedly, one group reports accelerated
axonal regeneration in BACE1−/− mice after sciatic nerve crush
(Farah et al., 2011). No differences were found during the early
stages of Wallerian degeneration, but faster neurite outgrowth
and an increased number of regenerating sprouts were present in
BACE1−/− when compared to wild-type littermates. Clearance
of myelin debris from damaged nerve sites sets the stage for efﬁ-
cient axonal regeneration (Vargas et al., 2010) and is increased in
BACE1-deﬁcient mice, due to increased phagocytosis of BACE1-
deﬁcientmacrophages (Farah et al., 2011). Summedup, these stud-
ies suggest a myelination-independent role of BACE1 in axonal
regeneration by regulating two different pathways, the internal
growth state of damaged neurons as well as myelin clearance by
macrophages.
In addition to its role inmyelination, type IIINRG1 is a risk fac-
tor for schizophrenia (Stefansson et al., 2002;Williams et al., 2003).
This establishes an interesting link to behavioral phenotypes of
BACE1−/− mice that are considered rodent analogs of schizo-
phrenia, such as impaired prepulse inhibition, novelty-induced
hyperactivity, and cognitive deﬁcits (Savonenko et al., 2008). Sup-
porting the hypothesis of NRG1-dependent behavioral changes
in BACE1−/− mice, these animals respond to the antipsychotic
drug clozapine in a similar fashion as type III NRG1+/− mice
and feature a reduction in cortical ErB4–PSD95 complex forma-
tion, an important downstream event for successful type III NRG1
signaling (Hahn et al., 2006; Savonenko et al., 2008). Further-
more, NRG1 regulates expression levels of another schizophrenia
susceptibility factor, disrupted-in-schizophrenia-1 (DISC1), in an
ErbB2–ErbB3 dependent manner. Decreased DISC1 expression
levels are found in NRG1- as well as BACE1-knockout mice and
could explain shared behavioral phenotypes with mouse models
harboring DISC1 mutations (Kvajo et al., 2008; Seshadri et al.,
2010). These observations render BACE1 a putative drug target
for schizophrenia, while raising concerns for adverse side effects
upon therapeutic inhibition in AD. Notably, effective inhibition of
BACE1 in adult mice lowered Aβ levels but had no effect on NRG1
processing (Sankaranarayanan et al., 2008). Neuregulin 3 is also
processed by BACE1 in vivo, but no functional consequences have
been reported yet (Hu et al., 2008).
BACE1 SUBSTRATES: β-SUBUNITS 2 AND 4 OF VOLTAGE-GATED
SODIUM CHANNELS
The β-subunits 2 and 4 (Navβ2, Navβ4) of VGSCs are also known
to be processed by BACE1 under physiologic conditions. Besides
NRG1 they are amongst the best characterized BACE1 substrates
(reviewed in Kovacs et al., 2010). Navβs covalently bind to the
channel-forming α-subunits (Nav1) of VGSCs and regulate their
surface expression levels and inactivation kinetics (Catterall, 2000;
Isom, 2001). Cleavage of these β-subunits by BACE1 generates
a CTF that is further processed by γ-secretase, yielding an ICD
that is released into the cytosol (Wong et al., 2005). The ICD of
Navβ2 translocates to the nucleus and increases mRNA and pro-
tein levels of α-subunits, which in return alters sodium current
densities at the cell surface (Kim et al., 2007). Under overexpres-
sion conditions in vitro, Navβ1–4 are subject to RIP by BACE1
and resulting increases in Nav1.1 protein levels lead to intracellu-
lar accumulation of α-subunits in a HSP70 positive compartment.
This prevents in an unknown fashion the transport of functional
channels to the plasma membrane and leads to a decrease of
total VGSC surface levels. In vivo, CTFs of Navβ2 and Navβ4 are
reduced in the brains of BACE1-knockoutmice,whereas increased
Navβ2 processing and increased total levels Nav1.1 are found in
AD patients with elevated BACE1 activity (Wong et al., 2005; Kim
et al., 2007). BACE1-deﬁcient mice show reduced total and sur-
face expression levels of Nav1.1 in hippocampal neurons, with a
compensatory increase of Nav1.2 surface levels reported by two
groups, but not by another (Hitt et al., 2010; Hu et al., 2010; Kim
et al., 2011). Therefore, the regulation of Nav1.1 surface expression
by BACE1 in vivo seems to be regulated by the decrease of total
Nav1.1 levels. Distinct epilepsy syndromes are caused by muta-
tions in the Nav1.1 channel gene SCN1A and mice lacking Nav1.1
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suffer from a severe lethal seizure phenotype (Claes et al., 2001;
Mulley et al., 2005; Yu et al., 2006). Whether changes in sodium
channel current density in BACE1−/− mice relate to the spon-
taneous epileptiform abnormalities observed in 20–30% of these
animals remains unclear, as reports from different groups remain
contradictory, due to different extraction methods and measure-
ment of total, or surface levels of different Nav1 subtypes (Hitt
et al., 2010; Hu et al., 2010; Kim et al., 2011). Further complexity is
added by the fact that Navβs have been proposed to interact with
various other proteins to modulate cell–cell adhesion and migra-
tion, therefore altering the neuronal environment beyond sodium
current density (Isom, 2001, 2002; Brackenbury et al., 2008).
BACE1 SUBSTRATES: α2, 6-SIALYLTRANSFERASE
The TGN-resident β-galactoside α2, 6-sialyltransferase (ST6Gal1)
was the ﬁrst identiﬁed BACE1 substrate that possesses a type II
transmembrane topology (Kitazume et al., 2001). It is mainly
expressed in the liver and released into various body ﬂuids, such
as serum and milk, with enhanced secretion during acute phase
reactions (Kaplan et al., 1983;Weinstein et al., 1987; Sarnesto et al.,
1992; Kitagawa and Paulson, 1994). Hepatic BACE1 is the major
protease responsible for the release of ST6Gal1 into serum, as
ST6Gal1 serum levels are reduced to ∼30% in BACE1−/− mice,
with a ∼25% decrease in total sialylation of plasma glycopro-
teins (Kitazume et al., 2005; Sugimoto et al., 2007). A rat model
of Wilson’s Disease that features spontaneous hepatitis shows an
upregulation of hepatic BACE1 mRNA and increased ST6Gal1
serum levels, without affecting ST6Gal1 mRNA levels, suggesting
that hepatic damage may lead to increased BACE1 activity and
therefore secretion of ST6Gal1 (Kitazume et al., 2005). Unfortu-
nately, thephysiological signiﬁcanceof soluble glycosyltransferases
in the serum remains enigmatic.
PROCESSING OF OTHER KNOWN BACE1 SUBSTRATES
The second group of BACE1 substrates is known to be processed
in vivo, whereas the physiologic function of the shedding event
remains unclear. The P-selectin glycoprotein ligand-1 (PSGL-1) is
expressed on most leukocytes and mediates adhesion to endothe-
lial cells by binding to P-selectin during inﬂammation. This
ensures efﬁcient leukocyte recruitment and subsequent transmi-
gration into damaged or infected tissue in the CNS and peripheral
organs (reviewed in Chen and Geng, 2006; Carlow et al., 2009).
The type I transmembrane protein PSGL-1 has been shown to
be shed by BACE1 and ADAM10, in a similar fashion to type III
NRG1, with the BACE1 cleavage site being closer to the mem-
brane (Lichtenthaler et al., 2003). According to this study, PSGL-1
is cleaved in HEK293 cells and immortalized monocytes under
endogenous conditions, whereas CTFs of PSGL-1 are not pro-
duced in neurons of BACE1−/− mice overexpressing PSGL-1.
However, in an acute model of peritonitis the composition and
number of leukocytes transmigrating into inﬂamed tissue did
not differ between BACE1−/− and control mice, arguing against
major perturbations in leukocyte recruitment (Dominguez et al.,
2005). A third inﬂammatory protein besides ST6Gal1 and PSGL-
1, the interleukin-1 receptor II, is also shed by BACE1 (Kuhn
et al., 2007). Currently it is not known whether shedding of this
interleukin-1 decoy receptor occurs under endogenous condition
as very similar and therefore indistinguishable CTFs might be
produced by metalloproteases in a compensatory fashion upon
knockout of BACE1.
The low density lipoprotein receptor-related protein (LRP)
coimmunoprecipitates with BACE1 in human brain tissue and
shedding of overexpressed LRP in HEK cells is decreased after
BACE1 inhibitor treatment (von Arnim et al., 2005). No endoge-
nous processing by LRP has been demonstrated so far.
The short list of known BACE1 substrates may explain a minor
part of the observed phenotypes in BACE1−/− mice, but the
mechanisms for the deﬁcits in cognitive and emotional perfor-
mance, hyperactive behavior, schizophrenia like phenotypes, and
epileptic seizures are far from being understood (Harrison et al.,
2003; Hu et al., 2006, 2010; Willem et al., 2006; Savonenko et al.,
2008). Changes in myelination and epileptic seizure thresholds
may be only partially due to improper type III NRG1 and Navβ
processing, with other unknown substrates potentially contribut-
ing to this phenotype. The analysis of BACE1 substrates and the
related phenotypes is further complicated by the fact that many
substrates may be shared with other proteases, primarily met-
alloproteases, leading to alternative shedding events. This could
explain the sometimes only subtle phenotypic changes, as metal-
loproteases may mediate the major part of substrate processing or
even compensate for the lack of BACE1 dependent shedding, as
seen for the increased α-shedding of APP upon BACE1 inhibition
or knockout (Vassar et al., 1999; Sankaranarayanan et al., 2008;
Sala Frigerio et al., 2010).
In addition, BACE1 seems to play a major role outside the cen-
tral and peripheral nervous system. One group reports a fatality
rate of ∼40% in BACE1−/− mice, with a bimodal distribution 1
and 4 weeks after birth, while animals that survive to adulthood
weigh ∼30% less and are accordingly smaller than their wild-
type littermates (Dominguez et al., 2005). Additional deletion of
BACE2 increased the fatality rate to ∼60%. The lean phenotype
of BACE1−/− mice is associated with increased insulin sensitivity
as measured by increased phosphorylation of protein kinase B in
skeletal muscle and liver, improved whole body glucose disposal,
and resistance to diet induced obesity (Meakin et al., 2012). High
fat diet increased hepatic and muscular BACE1 expression in wild-
type and BACE1+/− mice and was accompanied by increased
insulin resistance. It is unknown how BACE1 regulates insulin
sensitivity, but this study provides further evidence for physio-
logic BACE1 functions outside the central and peripheral nervous
system.
To sum up, a large variety of unexplained phenotypes of the
nervous system as well as in peripheral tissues exist, and raise
concerns toward mechanism-based side effects upon therapeutic
inhibition. Unbiased, objective approaches toward the identiﬁca-
tion of novel BACE1 substrates are needed, with focus on the
CNS and peripheral organs involved in glucose metabolism, such
as pancreas, liver, and muscle. A shotgun proteomics approach
in HEK293 and HeLa cells uncovered several additional putative
BACE1 substrates (Hemming et al., 2009). Although the screen
identiﬁed several known BACE1 substrates along with numer-
ous putative new substrates, including type II transmembrane and
GPI-anchored proteins, it was based on overexpression of BACE1
in non-neuronal cell lines. Further validation of identiﬁed putative
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substrates is therefore necessary, as well as objective screening for
additional BACE1 substrates under endogenous conditions in pri-
mary cells, e.g., cortical neurons or pancreatic cells. This may
ultimately aid in the elucidation of phenotypes observed upon
BACE1-knockout or treatment with BACE1 inhibitors.
BACE2 SUBSTRATES
The BACE1 homolog BACE2 features the same structural and
catalytic properties as BACE1, but differs in regard to expres-
sion patterns and substrate speciﬁcity (reviewed in Stockley and
O’Neill, 2008). The highest expression levels are found in the β-
cells of pancreatic islets, whereas BACE2 activity in brain is very
low (Bennett et al., 2000a; Dominguez et al., 2005; Esterhazy et al.,
2011).AlthoughBACE2 cleavesAPP at the β-site to aminor extent,
the majority of APP cleavage occurs within the Aβ region in an
α-secretase-like fashion (Farzan et al., 2000; Hussain et al., 2000).
Whereas no Aβ could be detected in neurons, glial cells derived
from BACE1−/− mice still secrete an Aβ-like peptide that is no
longer detectable in BACE1/BACE2−/− mice, suggesting a con-
tribution of BACE2 to the total Aβ pool (Dominguez et al., 2005).
However, almost no Aβ is found in APP transgenic mice lack-
ing BACE1, arguing against a signiﬁcant contribution of BACE2
toward Aβ generation (Luo et al., 2001; Ohno et al., 2004). BACE2
in AD is thus mainly regarded as an anti-amyloidogenic protease.
BACE2 and BACE1 share a set of type I transmembrane proteins
as substrates, albeit with mostly distinct cleavage sites, as described
for APP and IL1R2 (Farzan et al., 2000; Fluhrer et al., 2002; Kuhn
et al., 2007). The physiologic relevance of substrate shedding by
BACE2 is largely unknown, as BACE2−/− mice appear healthy.
However, the increased lethality of BACE1/BACE2−/− mice com-
pared to BACE1−/− mice suggest essential common substrates
amongst these two proteases or at least activation of the same
pathways upon substrate processing. In addition,differences in tis-
sue speciﬁc expression levels, subcellular localization, and cleavage
sites betweenBACE1 andBACE2point to the existence of exclusive
substrates for either homolog.
The proproliferative type I transmembrane protein TMEM27
regulates the growth of pancreatic islets and has recently been
identiﬁed as the ﬁrst physiologically relevant BACE2 substrate
(Esterhazy et al., 2011). Interestingly, TMEM27 is not processed
by BACE1, which is in contrast to the majority of known BACE2
substrates. Full length TMEM27 acts in a proproliferative fash-
ion and increases pancreatic β-cell mass upon overexpression
in vivo. Ectodomain shedding inactivates the protein, as neither
the secreted ectodomain nor the remaining CTF display signaling
activity (Akpinar et al., 2005). BACE2−/− mice show a similar
metabolic phenotype as mice overexpressing TMEM27 and accu-
mulate full length TMEM27 in their pancreatic islets (Esterhazy
et al., 2011). This suggests that increases in β-cell mass, insulin
secretion and improved glucose response in BACE2−/− mice are
at least partially due to increased TMEM27 protein levels and
related signaling events. Full length TMEM27 was also enriched in
pancreatic islets of BACE1−/−mice, but with a parallel increase in
secreted ectodomains, arguing for a cleavage-independent mech-
anism. Interestingly, BACE1 and BACE2 both regulate insulin
metabolism, however on the opposite ends of the same sig-
naling axis. BACE1 regulates insulin sensitivity, whereas BACE2
regulates insulin secretion. To conclude, our current knowledge
about BACE2 is still in its infancy, but the activity of most
BACE1 inhibitors toward BACE2 stresses the importance of future
research on BACE2 function and the related mechanism-based
side effects upon at least partial inactivation.
THERAPEUTIC INHIBITION OF BACE1
Reducing BACE1 activity by RNAi or complete deletion of the
BACE1 gene by homologous recombination leads to a dramatic
reduction in Aβ plaque load and improves memory deﬁcits and
cholinergic dysfunction in APP transgenic mouse lines, validat-
ing the potential therapeutic value of BACE1 inhibition in AD
(Ohno et al., 2004; Singer et al., 2005). The BACE1 crystal struc-
ture in complex with a transition-state inhibitor based onAPPSWE
promoted the design of an ever increasing quantity of active site
inhibitors,which cannot be listed here in their entirety (Hong et al.,
2000;Ghosh et al., 2001;Gruninger-Leitch et al., 2002;Turner et al.,
2002). These small molecules feature oral bioavailability and low
production costs, but the lack of speciﬁcity and the inefﬁcient pen-
etration of the blood–brain barrier (BBB) have prevented major
breakthroughs in the past. Successful pre-clinical, oral administra-
tion of a BACE1 inhibitor has been demonstrated in two studies,
one reporting a reduction of soluble Aβ in mouse brain, the other
a reduction in CSF Aβ levels in non-human primates (Sankara-
narayanan et al., 2009; Fukumoto et al., 2010). A recent study
reports for the ﬁrst time the efﬁcient inhibition of BACE1 with an
orally available, non-peptidic inhibitor in man, as measured by the
decrease of Aβ andAPPsβ in CSF (May et al., 2011). Unfortunately,
this proof of principle study had to be stopped during the clini-
cal phase I trial due to retinal pathology observed upon long-term
administration of the inhibitor in a pre-clinical mouse model. The
pathology was recapitulated in BACE1−/− mice, speaking against
mechanism-based toxicity. However, 11 years after the initiation of
BACE1 inhibitor development, designing drugs that are lipophilic
and small enough (<700 Da) to cross the BBB while still being able
to block the unusually large catalytic site of BACE1 remains one
of the main challenges in the ﬁeld. In order to improve the efﬁ-
ciency of small molecule active site inhibitors, one group reports
the design of a transition-state inhibitor linked to a sterol moiety,
resulting in increased localmembrane concentration and inhibitor
potency (Rajendran et al., 2008).
A rather novel approach exploits the selectivity of therapeutic
antibodies directed against BACE1. The reported antibodies rec-
ognize unique, non-catalytical exosites of BACE1 and inhibit its
proteolytic activity in vitro as well as in mice and non-human pri-
mates (Atwal et al., 2011; Zhou et al., 2011). To further increase
the therapeutic value of these antibodies, a bispeciﬁc antibody
was generated, with one arm consisting of a high-afﬁnity BACE1
antibody and the other arm consisting of a low-afﬁnity anti-
transferrin receptor antibody, thus speeding up receptor-mediated
transcytosis across the BBB and increasing the target antibody
concentration in the CNS (Yu et al., 2011). In order to bypass
the high costs and regular parenteral delivery of passive immu-
nization, one study reports active immunization with BACE1 in
APP transgenic mice that led to a signiﬁcant reduction of brain Aβ
without perceivable inﬂammatory side effects (Chang et al., 2007).
An unusual approach toward BACE1 inhibition targets the cellular
www.frontiersin.org February 2012 | Volume 3 | Article 8 | 9
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environment of BACE1 rather than inhibiting the enzyme directly.
Bepridil and amiodarone, two approved calcium antagonists that
containweakly basic amino groups, raise themembrane-proximal,
endosomal pH above the optimum pH value for BACE1 activity,
thus slowing Aβ production (Mitterreiter et al., 2010). Innovative
approaches that do not rely on BACE1 active site inhibition may
speed up the discovery of drugs that are small enough to penetrate
the BBB.
CONCLUSION AND OUTLOOK
BACE1 is the rate-limiting enzyme for Aβ generation in neu-
rons and thus a prime drug target in AD. The complex reg-
ulation of BACE1 activity, the increasing number of observed
phenotypes in knockout mice as well as the processing of mul-
tiple substrates besides APP speak for the versatile role of this
protease during development and adulthood but raise concerns
toward mechanism-based side effects. Despite extensive efforts, it
remains to be shown whether BACE1 inhibition may alleviate or
reverse symptoms of AD, as no BACE1 inhibitor has endured a
randomized human clinical trial. Combinatorial therapies, where
compounds targeting BACE1, γ-secretase and Aβ are combined
in a two or three drug regimen may be more efﬁcient and at
the same time offer less side effects, as partial inhibition of the
individual secretases may be sufﬁcient. It remains unclear, which
side effects may be of concern during the long-term adminis-
tration of BACE1 inhibitors that would be required to treat AD
patients. The generation of conditional BACE1−/− mice, where
the complete knockout could be initiated during adulthood, could
help to address this issue. Additionally, as with other Aβ lower-
ing strategies, it is currently unknown whether treatment must
be initiated in the prodromal phase of the disease or whether
therapeutic intervention during manifest AD is sufﬁcient to alter
cognitive decline. BACE1 is a rationale target in AD drug develop-
ment, but there is still much to be learned about the physiologic
function of BACE1, its precise localization in polarized cells such
as neurons, and the role of the lipid microenvironment on enzy-
matic activity. The identiﬁcation of novel BACE1 substrates as
well as detailed mechanistic studies on existing BACE1 substrates
will be of importance to uncover mechanism-based side effects
as well as discovering new biomarkers for AD. The latter part is
of utmost importance, as therapeutic intervention even before
the onset of clinical symptoms may be necessary to alter disease
progression.
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